DE60013126D1 - Ophthalmische histamin-enthaltende zusammensetzungen und deren verwendung - Google Patents

Ophthalmische histamin-enthaltende zusammensetzungen und deren verwendung

Info

Publication number
DE60013126D1
DE60013126D1 DE60013126T DE60013126T DE60013126D1 DE 60013126 D1 DE60013126 D1 DE 60013126D1 DE 60013126 T DE60013126 T DE 60013126T DE 60013126 T DE60013126 T DE 60013126T DE 60013126 D1 DE60013126 D1 DE 60013126D1
Authority
DE
Germany
Prior art keywords
ophthalmic
histamine
compositions
histamine compositions
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60013126T
Other languages
English (en)
Other versions
DE60013126T2 (de
Inventor
R Gehlsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maxim Pharmaceuticals Inc
Original Assignee
Maxim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxim Pharmaceuticals Inc filed Critical Maxim Pharmaceuticals Inc
Application granted granted Critical
Publication of DE60013126D1 publication Critical patent/DE60013126D1/de
Publication of DE60013126T2 publication Critical patent/DE60013126T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60013126T 1999-06-03 2000-06-02 Ophthalmische histamin-enthaltende zusammensetzungen und deren verwendung Expired - Fee Related DE60013126T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13756499P 1999-06-03 1999-06-03
US137564P 1999-06-03
PCT/US2000/015379 WO2000074649A2 (en) 1999-06-03 2000-06-02 Ophthalmic histamine compositions and uses thereof

Publications (2)

Publication Number Publication Date
DE60013126D1 true DE60013126D1 (de) 2004-09-23
DE60013126T2 DE60013126T2 (de) 2005-09-08

Family

ID=22478011

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60013126T Expired - Fee Related DE60013126T2 (de) 1999-06-03 2000-06-02 Ophthalmische histamin-enthaltende zusammensetzungen und deren verwendung

Country Status (11)

Country Link
US (1) US6531120B2 (de)
EP (1) EP1187611B1 (de)
AT (1) ATE273704T1 (de)
AU (1) AU777655B2 (de)
CA (1) CA2376108A1 (de)
DE (1) DE60013126T2 (de)
DK (1) DK1187611T3 (de)
ES (1) ES2225156T3 (de)
HK (1) HK1045458B (de)
PT (1) PT1187611E (de)
WO (1) WO2000074649A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2439119A1 (en) 2001-02-28 2002-09-06 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
MXPA03007785A (es) 2001-02-28 2003-12-08 Merck & Co Inc Derivados de piperidina acilados como agonistas del receptor de melanocortina 4.
CA2453609C (en) 2001-07-18 2010-05-04 Merck & Co., Inc. Bridged piperidine derivatives as melanocortin receptor agonists
WO2003082081A2 (en) * 2002-03-29 2003-10-09 Maxim Pharmaceuticals, Inc. Use of rom production and release inhibitors to treat and prevent intraocular damage
AU2003268493A1 (en) 2002-09-11 2004-04-30 Merck & Co., Inc. Piperazine urea derivatives as melanocortin-4 receptor agonists
US7071211B2 (en) * 2002-09-27 2006-07-04 Bausch & Lomb Inc. Small organic molecules that increase the activity of gelatinase a in ocular cells
JP4754219B2 (ja) * 2002-12-02 2011-08-24 アムジエン・フレモント・インコーポレイテツド 腫瘍壊死因子を対象とする抗体、およびそれらの使用
DE10362141B4 (de) * 2003-03-19 2008-08-21 Johnson Controls Gmbh Feststell- und Neigungsverstellung für Beschläge
US20040248959A1 (en) * 2003-04-30 2004-12-09 Bender Scott C. Histamine containing eye drops for visual identification of lymphoid tissue within the tissues of the eye, that are to be samples for further diagnostic testing
JP4834829B2 (ja) * 2005-03-31 2011-12-14 国立大学法人山口大学 クラミジア属細菌の抑制に効果のあるトリプトファン代謝中間産物
US10165772B2 (en) * 2008-08-21 2019-01-01 Édouard Kouassi Methods and compounds for increasing red blood cell survival
CN104337760B (zh) * 2013-08-02 2018-09-04 山东新时代药业有限公司 一种二盐酸组胺注射液及其制备方法
CN110075063A (zh) * 2019-05-27 2019-08-02 合肥亿帆生物医药有限公司 一种二盐酸组胺注射液及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4510145A (en) * 1980-12-02 1985-04-09 Schachar Ronald A Method for inhibiting contraction of ophthalmic wounds or incisions
US5679337A (en) * 1991-06-14 1997-10-21 Professional Pharmaceutical, Inc. Method and composition for topical treatment of Aphthous stomatitis histamine using phosphate as active ingredient
IL101441A (en) 1992-04-01 1999-07-14 Univ Ramot Pharmaceutical preparations for the treatment and prevention of diseases or irregularities in the eye
JP3631490B2 (ja) 1992-05-13 2005-03-23 ノバルティス ファーマ株式会社 シクロスポリン含有眼科用組成物
US5401327A (en) 1993-06-18 1995-03-28 Wilmington Partners L.P. Method of treating contact lenses
US5545617A (en) * 1993-11-12 1996-08-13 The Schepens Eye Research Institute, Inc. Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion
CA2160779C (en) * 1994-03-02 2008-08-26 Bruce A. Jack Method and composition for topical treatment of damaged tissue using histamine phosphate as active ingredient
US5861148A (en) 1995-01-23 1999-01-19 Smith; Stewart Gregory Ophthalmic compositions and process of using
US5895645A (en) 1995-01-31 1999-04-20 Bausch & Lomb Incorporated Opthalmic solution for artificial tears
US6071942A (en) * 1996-05-14 2000-06-06 Maxim Pharmaceuticals, Inc. Elevation of circulating blood histamine levels
WO1997044062A1 (en) * 1996-05-23 1997-11-27 Alcon Laboratories, Inc. The use of 5-ht1b/1d agonists to treat ocular pain
WO1998018458A1 (en) * 1996-10-31 1998-05-07 Alcon Laboratories, Inc. Opthalmological compositions containing serotonin 5-ht1a receptor agonist and their use in the treatment of glaucoma
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6270781B1 (en) * 1999-01-08 2001-08-07 Maxim Pharmaceuticals, Inc. Method and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors

Also Published As

Publication number Publication date
ES2225156T3 (es) 2005-03-16
WO2000074649A2 (en) 2000-12-14
US20020098224A1 (en) 2002-07-25
DE60013126T2 (de) 2005-09-08
US6531120B2 (en) 2003-03-11
EP1187611B1 (de) 2004-08-18
DK1187611T3 (da) 2004-10-11
EP1187611A2 (de) 2002-03-20
ATE273704T1 (de) 2004-09-15
HK1045458B (zh) 2005-03-24
CA2376108A1 (en) 2000-12-14
PT1187611E (pt) 2004-10-29
AU5462700A (en) 2000-12-28
HK1045458A1 (en) 2002-11-29
WO2000074649A3 (en) 2002-01-17
AU777655B2 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
MX9707453A (es) Derivados de quinazolina.
DE60013126D1 (de) Ophthalmische histamin-enthaltende zusammensetzungen und deren verwendung
MY106259A (en) 2-aminopyrimidinone derivatives.
BR9913800A (pt) Método para tratar glaucoma, e, composição para tratar glaucoma
AU2003301020A8 (en) Isoquinolinone derivatives and their use as therapeutic agents
HK1036931A1 (en) Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients.
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
ATE235893T1 (de) Orale zubereitung enthaltend zonula occludens toxin und einen biologisch aktiven wirkstoff sowie deren verwendung
TR200102977T2 (tr) Yeni tedavi yöntemi.
GEP20033079B (en) Pharmaceutical Compositions for Treatment of Diseases Caused by Estrogens Deficiency
BRPI0008228B8 (pt) composição farmacêutica contendo n-benzoil estaurosporina e agentes solubilizantes
ES2194055T3 (es) Nuevo uso de prostaglandinas.
IT1255802B (it) Derivati imidazolici ad attivita' a ii antagonista
WO2000018316A3 (en) Sustained release, and comfortable ophthalmic composition and method for ocular therapy
SE9802208D0 (sv) Novel compounds
NZ237309A (en) 1-(2-(4-morpholino)ethyl)-3-(arylcarbonyl)-indole derivatives and pharmaceutical compositions
NZ514558A (en) Viral treatment
WO1998039293A3 (en) 13-thia prostaglandins for use in glaucoma therapy
ATE197401T1 (de) Chinazolinon-arzneimittel sowie deren verwendung
DE60106953D1 (de) Adenosinderivate und deren verwendung
PT1000046E (pt) Derivados de piperazina activos no trato urinario inferior
ATE218535T1 (de) Aminotetralinderivate, deren zusammensetzungen sowie deren verwendung
IL126725A0 (en) Compositions comprising a nitrone compound for use in treating ocular inflammation
PL339073A1 (en) Derivatives of benzoxazine and benzothiazine and their application in therapeutic agents
WO1999061059A8 (fr) Compositions de minoxidil pour usage externe

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee